Thus, further studies are required to elucidate the role of APE1/Ref‐1 in dystrophic muscle either via the generation of muscle‐specific knock‐in/out models, or by implementing APX3330 at an earlier time point during periods of heightened damage and repair, offering the most ‘treatable’ age consistent with DMD being a pediatric disease. This evidence concerns the gene APEX1 and Duchenne muscular dystrophy.